Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease

Liver International

Volumn 33, Issue 8, 2013, Pages 1203-1210

  Chen, Fei W ^a   Coyle, Luke ^a,c   Jones, Brett E ^a,c   Pattullo, Venessa ^a,b,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Concord Repatriation and General Hospital ^*  (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Chemotherapy; Entecavir; Haematological disease; Hepatitis B reactivation; Immunosuppression; Lamivudine

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BILIRUBIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; METHOTREXATE; RITUXIMAB; STEROID; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER FAILURE; MALE; MORTALITY; RETROSPECTIVE STUDY; STEROID THERAPY; VIRUS LOAD; VIRUS REACTIVATION;

CHEMOTHERAPY; ENTECAVIR; HAEMATOLOGICAL DISEASE; HEPATITIS B REACTIVATION; IMMUNOSUPPRESSION; LAMIVUDINE;

AGED; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEMATOLOGIC DISEASES; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84881549118     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12154     Document Type: Article

References (24)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 2004; 11: 97-107.
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. Borentain P, Colson P, Coso D, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepatitis 2010; 17: 807-15.
4. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol 2011; 46: 9-16.
5. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
6. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
7. Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011; 46: 556-64.
8. Morisco F, Castiglione F, Rispo A, et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011; 43(Suppl. 1): S40-8.
9. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-71.
10. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009; 7: 1130-7.
11. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
12. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47: 844-53.
13. Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepatitis 2011; 18: 877-83.
14. Villeneuve JP. The natural history of chronic hepatitis B virus infection. J Clin Virol 2005; 34(Suppl. 1): S139-42.
15. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49(5 Suppl): S156-65.
16. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19: 1276-82.
17. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
18. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
19. Colson P, Borentain P, Coso D, et al. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 143: 148-50.
20. O'Sullivan BG, Gidding HF, Law M, et al. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004; 28: 212-6.
21. Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010; 89: 255-62.
22. Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 2012; 19: 32-8.
23. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 2008; 83: 673-5.
24. Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010; 91: 501-8.